A Phase 2 Clinical Trial To Evaluate The Immune Restoration Potential Of Lenalidomide For Patients With CLL-Associated Immunodeficiency

Trial Profile

A Phase 2 Clinical Trial To Evaluate The Immune Restoration Potential Of Lenalidomide For Patients With CLL-Associated Immunodeficiency

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 26 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 26 Sep 2016 Planned initiation date changed from 1 Apr 2015 to 1 Feb 2017.
    • 11 Jan 2016 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top